ASX ANNOUNCEMENT 26 July 2021

Cynata Appoints Dr Jolanta Airey Chief Medical Officer

Melbourne, Australia; 26 July 2021: Cynata Therapeutics Limited (ASX: "**CYP", "Cynata",** or the **"Company"**), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the appointment of Dr Jolanta Airey as Chief Medical Officer (CMO).

Highlights:

- **Former senior clinical position with CSL Limited in clinical development**
- **Dr Airey brings over 25 years' experience in respiratory, rheumatology, dermatology, biologicals, international markets and listed companies and is a highly experienced clinician**
- **Appointment is consistent with Cynata's growing clinical trial activities and late-stage clinical product portfolio**

Dr Airey is an accomplished biopharmaceutical executive and physician with broad international experience in the successful development and commercialisation of pharmaceutical products including novel biological agents. She has been involved in the design and execution of multiple clinical trials from early through to late stage, encompassing a wide range of therapeutic categories in multiple geographies. Dr Airey is expected to join Cynata in October from CSL Limited where she is currently Director, Translational Development. Previously Dr Airey was a Clinical Development Physician at Seqirus, a CSL company, and earlier held a range of medical positions within biotech, pharmaceutical and clinical research companies. Her career path has led to her playing important roles in the market approvals of several drug products.

Dr Ross Macdonald, Cynata's Chief Executive Officer, said:
"Jolanta joins Cynata at a very significant point in the Company's growth with multiple clinical trials now underway and exciting additional programs in development. Her extensive experience and capability will be important as we extend our product development activities across international jurisdictions and maximise commercial opportunities to build shareholder value."

Dr Airey said:
"I am thrilled to be joining Cynata at such an exciting time. The potential clinical utility of Cynata's proprietary Cymerus™ mesenchymal stem cell technology across a wide range of advanced therapeutic targets provides robust commercial opportunities. I look forward to adding my skills to the team and to seeing Cynata's products move successfully toward the market and widespread clinical use."

Dr Airey will be granted 1,000,000 options under the Company's Employee Option Acquisition Plan (**Options**) on the commencement date of her employment. The Options will have an exercise price representing a 45% premium to the volume weighted average price of CYP shares traded on ASX over the five business days prior to the grant of the Options. The Options will expire four years after they are granted. The first tranche of 200,000 Options will be fully vested on grant. The remaining 800,000 Options will vest over 24 months, in equal monthly tranches, commencing on the one year anniversary of Dr Airey's commencement date. The vesting of the Options is subject to Dr Airey's continued employment.

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

Cynata Therapeutics Limited
Level 3, 100 Cubitt Street, Cremorne, Victoria, 3121, Australia
PO Box 7165, Hawthorn North, Victoria 3122
T: +61 3 7067 6940 E: info@cynata.com
ABN – 98 104 037 372

CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, ross.macdonald@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, laurenmaree@live.com.au

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Clinical trials of Cymerus MSC products in osteoarthritis (Phase 3) and in patients with respiratory failure are currently ongoing. Planning is also underway for further clinical trials of Cymerus MSC products in GvHD (through licensee Fujifilm), diabetic foot ulcers, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.